The Guanabenz trial Statistical Analysis Plan, Data Management Plan and Data Validation and Derivation plan are available

The core protocol for phase 2/3 clinical trial(s) in VWM is now published

Calico Life Sciences Announces First Participant Dosed in Phase 1b Clinical Study Evaluating ABBV-CLS-7262 for the Treatment of Vanishing White Matter Disease